Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Proof-of-concept Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder
Latest Information Update: 27 Dec 2023
At a glance
- Drugs Nivasorexant (Primary)
- Indications Binge-eating disorder
- Focus Proof of concept; Therapeutic Use
- Sponsors Idorsia Pharmaceuticals
- 01 Nov 2023 Results of Efficacy, safety, and tolerability of nivasorexant in adults with binge-eating disorder, published in the International Journal of Eating Disorders
- 10 May 2022 According to an Idorsia Pharmaceuticals media release, the company will now fully analyze the data and publish the results of the study in scientific literature in due course.
- 10 May 2022 Results published in the Idorsia Pharmaceuticals Media Release.